EcoDrugPlus

C-X-C Motif Chemokine Ligand 8

Ensembl ID : ENSVPAG00000003177
Gene Symbol: CXCL8
1 Cross references
183 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSVPAG00000010093
Gene Symbol: CXCR4
1 Cross references
283 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSVPAG00000008758
Gene Symbol: CFTR
3 Cross references
216 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSVPAG00000011153
Gene Symbol: TOP1
1 Cross references
270 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSVPAG00000001177
Gene Symbol: TOP2A
1 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSVPAG00000009207
Gene Symbol: TOP2B
1 Cross references
208 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSVPAG00000009945
Gene Symbol: EML4
1 Cross references
209 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSVPAG00000000339
Gene Symbol: EPHA3
1 Cross references
215 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSVPAG00000005205
Gene Symbol: FAU
1 Cross references
202 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSVPAG00000011294
Gene Symbol: FYN
1 Cross references
261 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSVPAG00000007833
Gene Symbol: ITK
1 Cross references
207 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSVPAG00000006184
Gene Symbol: JAK1
1 Cross references
236 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).